Suven Life secures patents in Canada, Hong Kong

Hyderabad: Suven Life Sciences Ltd has obtained two patents, one each from Hong Kong and Canada, for its New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

The granted claims of the patents include the class of selective 5-HT compounds discovered by the Hyderabad-based company that were being developed as therapeutic agents.

They were useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinsons and schizophrenia.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.